Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

Stay up-to-date on the latest stock market upgrades and downgrades on Wall Street, including companies like Roku, Palo Alto ...

Alzheimer's wonder drugs aren't yet delivering on their promise. American researchers have come up with a brand new idea, a ...

Needham has recently reduced Biogen Inc (BIIB) stock to Hold rating, as announced on November 18, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated the stock to ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this ...

A large majority of RRMS patients experienced no evidence of disease activity for up to six years on Tysabri, a real-world ...

Needham has recently reduced Biogen Inc (BIIB) stock to Hold rating, as announced on November 18, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated the stock to ...

Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.

Samsung Biologics has announced another significant manufacturing agreement, securing a $668m contract with a Europe-based ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...